Does Mounjaro Affect Blood Tests — and What Should You Tell Your Doctor?

The misconception: that blood-test changes on Mounjaro signal something going wrong

The most common worry people bring to this question is that a result flagged as 'outside the normal range' after starting Mounjaro means the medicine has caused harm. That's almost always the wrong reading. Many of the blood-test shifts associated with tirzepatide are pharmacological effects that were anticipated in clinical trials and, in most cases, represent the medicine doing exactly what it was designed to do. Knowing this in advance saves a lot of anxiety when a letter about a 'low HbA1c' lands on your doormat.

That said, no change should be dismissed without context. The right question is not 'did my result move?' but 'what does this movement mean for me, given that I am taking tirzepatide?' Your prescriber and your GP both need to know you are on treatment before interpreting results. If you are a transfer patient or have recently increased your dose, the timing of the test matters too. Our clinical team page gives you a sense of how our prescribers approach ongoing clinical oversight.

There is also a separate (and reasonable) question about whether Mounjaro itself will show up on a blood test. It is not part of any routine panel, so it will not appear unless a lab specifically tests for tirzepatide, which is not something that happens in NHS clinical practice. You can read more about whether Mounjaro shows up in blood tests if that is what you were searching for.

Blood glucose, HbA1c and the markers most likely to change

Tirzepatide activates both GLP-1 and GIP receptors, which together stimulate insulin release in response to food and suppress glucagon. The direct result: fasting blood glucose falls, and over weeks to months, HbA1c (the three-month average of blood-sugar control) falls with it. For people without diabetes this can push readings into territory a GP might query if they do not know the patient is on treatment. For people with type 2 diabetes it is frequently a striking and welcome improvement, though it also means that anyone on insulin or sulphonylureas alongside Mounjaro needs prescriber review to avoid hypoglycaemia.

The NHS medicines page for tirzepatide lists hypoglycaemia as a side effect specifically in the context of combination with other glucose-lowering medicines, it is not a risk in people with normal glucose regulation on Mounjaro alone. Understanding how this medicine interacts with blood-sugar physiology is also covered in detail on our page about how Mounjaro affects blood sugar.

Lipid panels also shift. Triglycerides tend to fall meaningfully, and LDL cholesterol often improves, particularly as body weight reduces. The pattern seen in SURMOUNT-1 (where participants lost an average of around 20% of body weight over 72 weeks) included favourable cardiometabolic changes across multiple markers. A cholesterol reading taken six months into treatment is simply not the same clinical picture as one taken before treatment started.

Liver enzymes, kidney markers and what 'mild elevation' can mean

ALT and AST (the liver enzymes most commonly measured in standard blood panels) can be transiently elevated in some people starting tirzepatide, particularly if gastrointestinal side effects lead to changes in eating patterns or if the liver is adapting to rapid changes in fat metabolism. Clinically significant liver damage is not an established effect of tirzepatide, but any sustained or steep enzyme rise should be discussed with your prescriber rather than ignored. Over the medium to long term, studies have generally shown improving liver markers alongside weight loss, which is one reason semaglutide has now received regulatory attention for fatty liver disease.

Kidney function is worth mentioning separately because it is less obvious. Creatinine and eGFR are sensitive to hydration status. If you have experienced significant nausea or vomiting (especially during the early weeks of treatment) and are not drinking enough fluid, a creatinine reading may drift upward and eGFR may dip. This is a hydration effect, not direct kidney toxicity, but it needs the same clinical attention. The NICE appraisal of tirzepatide, TA1026, covers the broader safety monitoring framework that informed the medicine's UK licence. Staying on top of fluid intake is genuinely important; it is not just boilerplate advice.

If you are monitoring blood pressure alongside treatment, there is a companion page on how Mounjaro can affect blood pressure readings that is worth reading alongside this one. The picture across cardiometabolic markers is interconnected, and your GP will be looking at the whole panel together.

Practical steps before and after a blood test on Mounjaro

A few things make a real difference. Tell the clinician requesting the test that you are on tirzepatide, before the test, not as an afterthought when results arrive. If the test is fasting (HbA1c often is not, but glucose and some lipid panels are), your usual pre-test instructions apply; our page on Mounjaro blood tests walks through what to expect and how to prepare, so you are not caught off guard by the process. Though its effect on gastric emptying means the question of when to take Mounjaro around a blood test is one our prescribers are asked regularly.

It is also worth making sure your GP is aware you are taking Mounjaro, in line with GPhC guidance on GP notification, we do this as standard. That way, if your surgery runs routine bloods and gets back results that look different from last year's, the context is already on your record.

If any results come back and you are unsure whether they are related to treatment, our prescribers can help you make sense of them. A general overview of how Mounjaro works may also help you frame the right questions for your GP. If you are ready to start treatment or move across from another provider, you can start your free consultation and a GPhC-registered prescriber will review your information the same day.